# Treatment With SU11248 in Patients With Neuroendocrine Tumors

> **NCT00056693** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 107 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT00056693
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** 2006-09
- **Final completion:** 2006-09
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2008-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00056693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00056693, "Treatment With SU11248 in Patients With Neuroendocrine Tumors". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00056693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*